Identification of prognostic immune-related signature predicting the overall survival for colorectal cancer.

CONCLUSIONS: To summarize, we identified a novel 14-gene immune-related signature that may potentially serve as a prognostic predictor for colorectal cancer, thereby contributing to patient personalized treatment decisions. Further research needs to be conducted to validate the prognostic value of the selected genes. PMID: 32096169 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Related Links:

Sufficient bowel preparation is crucial for successful screening and surveillance colonoscopy. However, rates of inadequate preparation are still high. We investigated the effects of reinforced patient education using a smartphone application software (APP) for colonoscopy preparation in participants in a CRC screening program.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Lynch syndrome is the most common inherited cause of colorectal cancer (CRC). Contemporary and mutation-specific estimates of CRC-risk in patients undergoing colonoscopy would optimize surveillance strategies. We performed a prospective national cohort study, using data from New Zealand, to assess overall and mutation-specific risk of CRC in patients with Lynch syndrome undergoing surveillance.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
In addition to monitoring adverse events (AEs) and post-colonoscopy colorectal cancers (PCCRC), indicators for assessing colonoscopy quality include adenoma detection rate (ADR) and cecal intubation rate (CIR). It is unclear whether there is an association between annual colonoscopy volume and ADR, CIR, AEs, or PCCRC.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
British Journal of Cancer, Published online: 31 March 2020; doi:10.1038/s41416-020-0819-5Comment on: “Exploring the best treatment options for BRAF-mutant metastatic colon cancer”
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Colorectal Neoplasms Intervention:   Drug: PD-L1 Monoclonal Antibody Combined With Lenalidomide Sponsor:   Lining Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: June 2020Source: Cancer Epidemiology, Volume 66Author(s): Erik Frostberg, Hans B. Rahr
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Contributors : Dimitrios Iliopoulos ; Marina KoutsioumpaSeries Type : Non-coding RNA profiling by array ; Expression profiling by arrayOrganism : Homo sapiensTranscriptional lncRNAs expression comparing human colon cancer tissues to normal colon tissues using Agilent-062918 Human lncRNA array V4.0.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Expression profiling by array Homo sapiens Source Type: research
Journal of Natural ProductsDOI: 10.1021/acs.jnatprod.0c00003
Source: Journal of Natural Products - Category: Biochemistry Authors: Source Type: research
CONCLUSIONS HtrA1 rs1049331 polymorphism, but not rs11200638 polymorphism, can influence individual sensitivity to 5-FU-based treatment in stage III colon cancer patients. PMID: 32218415 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Genetics | Study